Literature DB >> 9260069

The expanding indications for clozapine.

C R Young1, J G Longhurst, M B Bowers, C M Mazure.   

Abstract

Clozapine is increasingly being used for clinical indications in addition to treatment-resistant schizophrenia; this article reviews the relevant literature. The first section reassesses the risks associated with clozapine treatment, particularly agranulocytosis. The next section discusses its use for schizophrenia in patients who are treatment resistant, not treatment resistant, and intolerant of traditional drug treatments. Subsequent sections address its use in mood disorders, neurologic conditions, comorbid substance abuse, aggressive behavior, and childhood schizophrenia. Each includes the initial rationale for the use of clozapine in the disorder, a critical evaluation of the relevant literature, and theories as to why clozapine's unique pharmacodynamic profile may be efficacious for the specific condition. This body of literature suggests clozapine may be an effective treatment for a wide range of disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260069     DOI: 10.1037//1064-1297.5.3.216

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  9 in total

1.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

Review 2.  The role of antipsychotics in smoking and smoking cessation.

Authors:  Annette M Matthews; Vanessa B Wilson; Suzanne H Mitchell
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

3.  Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats.

Authors:  Joseph H Porter; Adam J Prus; Robert E Vann; Stephen A Varvel
Journal:  Psychopharmacology (Berl)       Date:  2004-08-13       Impact factor: 4.530

4.  The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats.

Authors:  Adam J Prus; Alan L Pehrson; Scott D Philibin; Jesse T Wood; Sarah A Vunck; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2008-08-07       Impact factor: 4.530

5.  Olanzapine improves deficient sensory inhibition in DBA/2 mice.

Authors:  Johanna K Simosky; Robert Freedman; Karen E Stevens
Journal:  Brain Res       Date:  2008-07-25       Impact factor: 3.252

Review 6.  Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

7.  Predictors of response in a sample of treatment-resistant psychotic patients on clozapine.

Authors:  Antonio Ciapparelli; Francesca Ducci; Claudia Carmassi; Marina Carlini; Rosemma Paggini; Mario Catena; Matteo Bottai; Liliana Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-10       Impact factor: 5.270

8.  Clozapine-induced bowel infarction: a case report.

Authors:  Nicholas D McKinnon; Alvi Azad; Brian M Waters; Kaustubh G Joshi
Journal:  Psychiatry (Edgmont)       Date:  2009-03

9.  Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis.

Authors:  Daniela Polese; Michele Fornaro; Mario Palermo; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2019-04-17       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.